uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
FEC mobilized stem cells for high-dose therapy in breast cancer patients
Uppsala University, Medicinska vetenskapsområdet, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Oncology.
Show others and affiliations
1999 In: Acta Oncologica, ISSN 0284-186, Vol. 38, no 2, 239-245 p.Article in journal (Refereed) Published
Place, publisher, year, edition, pages
1999. Vol. 38, no 2, 239-245 p.
Identifiers
URN: urn:nbn:se:uu:diva-91125OAI: oai:DiVA.org:uu-91125DiVA: diva2:163735
Available from: 2003-11-27 Created: 2003-11-27Bibliographically approved
In thesis
1. Individually Tailored Toxicity-based Chemotherapy: Studies on Patients with Primary and Metastatic Breast Cancer
Open this publication in new window or tab >>Individually Tailored Toxicity-based Chemotherapy: Studies on Patients with Primary and Metastatic Breast Cancer
2003 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Standard dosing of chemotherapy based on body surface area (BSA) results in large individual differences in toxicity due to a large inter-patient variability in pharmacokinetics (PK) and pharmacodynamics (PD). This results in under-dosing in certain patients with a potentially weaker antitumoral effect.

Three clinical studies of individually tailored dosing of chemotherapy, based on haematological toxicity were conducted. In the first study, 26 women with metastatic breast cancer were treated with tailored and dose-escalated 5-fluorouracil, epirubicin and cyclophosphamide, supported by G-CSF (dFEC). In the second study 525 patients with high-risk primary breast cancer were randomised between dFEC and high-dose chemotherapy with autologous bone-marrow transplantation. The feasibility of a FEC regimen with doubled cyclophosphamide dose to mobilise peripheral stem cells was investigated. In the third study, 44 metastatic patients were treated with tailored epirubicin and docetaxel (ET). PK and PD were also investigated in these patients. The potential effects of G-CSF on MRI tumour evaluation were studied in 18 patients with skeletal metastases.

Toxicity-based dosing entailed an evenly distributed two- to three-fold range of tolerated doses in all three studies. Efficacy and toxicity were not correlated to tolerated dose-levels. Tailored dFEC resulted in a response rate of 81% and the same regimen resulted in fewer breast cancer relapses compared with standard FEC followed by high-dose therapy. Toxicity was manageable except for an increased rate of secondary leukaemia. The modified FEC could safely mobilise sufficient numbers of stem-cells. Tailored ET resulted in a response rate of 63%. The inter-individual variability in drug clearance was larger than the inter-occasion variability and a semi-physiological model of PK and PD could predict leukocyte nadir and duration. An increased diffuse MR signal in the long TE IR-TSE sequence was observed in normal bone-marrow during G-CSF treatment; this could be mistaken as disseminated metastatic disease and could obscure focal metastases.

In conclusion, the concept of individually tailored toxicity-based dosage of chemotherapy was equally feasible in primary and metastatic breast cancer, in two different chemotherapy regimens and in treatment with or without G-CSF support and may provide a pragmatic way of overcoming the shortcomings of standard BSA-based dosing.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2003. 79 p.
Series
Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 0282-7476 ; 1310
Keyword
Oncology, breast cancer, tailored chemotherapy, toxicity-based dosing, high-dose therapy, MR imaging, G-CSF, epirubicin, docetaxel, cyclophosphamide, 5-fluorouracil, Onkologi
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-3802 (URN)91-554-5817-3 (ISBN)
Public defence
2003-12-20, Rudbecksalen, Rudbecklaboratoriet, Uppsala, 09:15
Opponent
Supervisors
Available from: 2003-11-27 Created: 2003-11-27Bibliographically approved

Open Access in DiVA

No full text

By organisation
Oncology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 357 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf